{"id":1514,"date":"2016-08-29T17:51:10","date_gmt":"2016-08-29T12:21:10","guid":{"rendered":"https:\/\/delveinsightblog.wordpress.com\/?p=1119"},"modified":"2025-05-05T16:31:45","modified_gmt":"2025-05-05T11:01:45","slug":"pd-1-and-pdl-1-immune-check-point-inhibitors-a-prodigious-revolution-in-cancer-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pd-1-and-pdl-1-immune-check-point-inhibitors-a-prodigious-revolution-in-cancer-treatment","title":{"rendered":"PD-1 and PDL-1 Immune Check Point Inhibitors: A Prodigious Revolution in Cancer Treatment"},"content":{"rendered":"

Immune checkpoints are defined as the stimulatory or co-stimulatory molecules involved in the immune system. There are two kinds of checkpoint proteins found on T cells such as PD-1\/PD-L1 and cytotoxic T lymphocytes\u00a0(CTLA-4). The PD1\/PD-L1 pathway is an adaptive immune resistance mechanism exerted by tumor cells in response to endogenous anti-tumor activity. PD-1, a\u00a0protein\u00a0present in humans encoded by the\u00a0PDCD1\u00a0gene<\/a>, binds to two\u00a0ligands-\u00a0PD-L1<\/a>\u00a0and\u00a0PD-L2<\/a> to prevent the activation of T-cells by regulating the immune system. PD-L1 is a protein present in human encoded by CD274 gene that reduces the proliferation of CD8+ T cells at the lymph nodes by binding to PD-1 or B7.<\/p>\n

Immune checkpoint inhibitors are type of drugs, usually antibodies, which block these proteins of the immune system cells. Inhibiting the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor leads to killing of tumor cells by T Cells. PD-1 and PD-L1 inhibitors are used as immunotherapy for treating various cancers such as Lung Cancer, Metastatic Renal Cell Carcinoma, Head and Neck Cancer and Melanoma. They also protect against immune-mediated tissue damage.<\/p>\n